Rheumatoid arthritis affects millions of Americans, gradually changing lives as it progresses from subtle joint discomfort to potentially severe mobility limitations. For those living with this ...

Please provide your email address to receive an email when new articles are posted on . As highlighted in recent advances in rheumatoid arthritis pathogenesis, researchers’ understanding of the ...

Features of immune system ageing can be detected in the earliest stages of rheumatoid arthritis (RA), even before clinical diagnosis, a new study has found which provides at-risk individuals with hope ...

Scientists investigating the naturally occurring immunopeptide PEPITEM have shown reductions in arthritic joint swelling to a ...

Morning joint stiffness easing with movement may signal Rheumatoid Arthritis, not routine strain. Early diagnosis and ...

NEW YORK, Nov 7 Reuters) - A closely watched experimental drug for rheumatoid arthritis being developed by Pfizer Inc significantly reduced symptoms and improved physical function, according to data ...

With the discovery of autoantibodies and other risk factors for rheumatoid arthritis (RA), researchers developed clinical trials to see whether the disease can be prevented entirely. In the past 10 ...

What is the TREM-1 receptor? A new review explores TREM-1's role in sepsis, rheumatoid arthritis, and neuroinflammation.

Persistent morning stiffness and joint pain could signal rheumatoid arthritis, an autoimmune condition. A doctor explains ...

BOSTON, Nov. 7 (Reuters) - Swiss drugmaker Roche Holding AG said on Wednesday that its experimental rheumatoid arthritis drug, Actemra, was effective in the second of five late-stage clinical trials.

Scientists investigating the naturally occurring immunopeptide PEPITEM have shown reductions in arthritic joint swelling to a ...